Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00589563 · OUTCOME

Non-relapse Mortality at 100 Days Post HSCT

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer · Source last updated 2014-09-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of patients with a NRM
Interval / dispersion
95% Confidence Interval
Time frame
100 day point estimate was provided

What was measured

Patients were evaluated for non-relapse mortality (NRM) throughout the study. Non-relapse mortality was considered any death not attributable to relapse or disease progression. The cumulative incidence of NRM was determined using competing risk analysis. Competing risks for NRM were death due to disease progression, relapse and nonengraftment.

Groups in this outcome

All Patients

All patients were analyzed as a single population. Stratification by conditioning regimen was not done.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Patients32

Reported measurements

Source class 1
Values in Percentage of patients with a NRM · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
All Patients9.4Not reported3.227.5Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3.2
        upper Limit
        27.5
        value
        9.4
denoms
  1. counts
    1. group Id
      OG000
      value
      32
    units
    Participants
description
Patients were evaluated for non-relapse mortality (NRM) throughout the study. Non-relapse mortality was considered any death not attributable to relapse or disease progression. The cumulative incidence of NRM was determined using competing risk analysis. Competing risks for NRM were death due to disease progression, relapse and nonengraftment.
dispersion Type
95% Confidence Interval
groups
  1. description
    All patients were analyzed as a single population. Stratification by conditioning regimen was not done.
    id
    OG000
    title
    All Patients
param Type
NUMBER
reporting Status
POSTED
time Frame
100 day point estimate was provided
title
Non-relapse Mortality at 100 Days Post HSCT
type
SECONDARY
unit Of Measure
Percentage of patients with a NRM

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice